49 results about "Right ventricular hypertrophy" patented technology

In some aspects, the invention teaches pharmaceutical compositions that include a TGF-beta ligand trap, and methods of using a TGF-beta ligand trap to treat, prevent, or reduce the progression rate of pulmonary hypertension (PH). The invention also provides methods of using a TGF-beta ligand trap to treat, prevent, or reduce the progression rate of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, right ventricular hypertrophy, diseases associated with excessive TGF-beta signaling, diseases associated with excessive GDF15 signaling, and diseases associated with excessive PAI-1 signaling. The invention further provides methods of using a TGF-beta ligand trap to reduce right ventricular systolic pressure in a subject.

The invention discloses application of hydroxysafflor yellow A in preparation of health care drugs or functional food for treating hypoxic pulmonary hypertension. The hydroxysafflor yellow A has the function of inhibiting pulmonary vascular structure remodeling and right ventricular hypertrophy caused by anoxia. The invention further relates to a method for extracting hydroxysafflor yellow A from traditional Chinese medicine safflower. According to the invention, a new technological means for researching and developing the safflower medicinal resource is provided, a research is made on the function of the effective component hydroxysafflor yellow A of safflower for inhibiting pulmonary hypertension, and the result indicates that the hydroxysafflor yellow A can effectively improve the pulmonary artery remodeling of hypoxic pulmonary hypertension rats and reduce pulmonary arterial pressure, so the hydroxysafflor yellow A is expected to be used in the prevention and treatment of pulmonary hypertension.

Methods are provided for preventing and treating pulmonary hypertension and right ventricular hypertrophy involving administering to a patient a caveolin peptide coupled to a cell permeating compound such as a cell permeating peptide.

The invention relates to a new use of a drug, and specifically relates to an effect of atorvastatin on preparation of a drug for treating pulmonary hypertension. The invention discovers for the first time that atorvastatin is capable of alleviating MCT (Monocrotaline)-induced pulmonary inflammation, and inhibiting pulmonary vascular remodeling, pulmonary artery rising and right ventricular hypertrophy without affecting the body circulating pressure; NF-kB is possible to play an important role in the MCT-induced pulmonary hypertension; the atorvastatin is capable of inhibiting the inflammatory reaction by reducing the expression of the MCT-induced pulmonary hypertension lung tissue NF-kB, and is capable of reducing pulmonary vascular remodeling and inhibiting the pulmonary artery high pressure rising; therefore, the atorvastatin can be applied to preparation of the drug for treating the pulmonary hypertension.

The invention relates to the field of pharmaceutical chemistry and particularly provides a polydatin (PD) derivative containing a NO (nitric oxide) donor. A PD (3,4',5-trihydroxystilbene-3-beta-D-glucoside)4' hydroxyl group and a corresponding nitrate ester are subjected to chemical reaction so as to generate the NO donor type PD derivative which is in ester bond connection. After being absorbed into a lung tissue, the compound is subjected to biological transformation and ester bond breakage so that a bulk pharmaceutical chemical PD and the NO donor are dissociated, the NO donor can release NO slowly, and NO and PD can play roles of reducing pulmonary hypertension, relieving right ventricular hypertrophy, improving the pulmonary vascular endothelium function and resisting lipid peroxide cooperatively. The NO donor type PD derivative has an application in the aspect of preparing medicaments for preventing or treating pulmonary hypertension and high altitude pulmonary edema diseases caused by oxygen deficiency.

The invention relates to novel pharmacological action of traditional Chinese medicine salvianolic acid A and application thereof in the preparation of products for preventing, relieving and / or treating pulmonary arterial hypertension and its complications. The salvianolic acid A has the advantages that the salvianolic acid A has the pharmacological action of relieving pulmonary circulation pressure rise, the pharmacological actions of relieving right heart failure due to pulmonary arterial hypertension, improving right ventricular hypertrophy and right ventricular enlargement, improving heart injury due to pulmonary arterial hypertension, and restoring from heart failure, and the pharmacological actions of lowering endothelin-1 level in pulmonary tissues, relieving pulmonary arterial remodeling and improving pathologic damage of pulmonary tissues; the salvianolic acid A is a monomer compound extracted from Salvia miltiorrhiza, has low toxicity, has a wide source range of material, has promising application and development prospect, is an ideal novel traditional Chinese medicine monomer for treating pulmonary arterial hypertension and its complications, and may be applied to prepare products for preventing, relieving and treating pulmonary arterial hypertension and its complications, such as chronic obstructive pulmonary emphysema, chronic pulmonary heart disease and heart failure.

Myocardial hypertrophy is a pathological change of a plurality of kinds of angiocardiopathy. The main mode is the heart remodeling comprising cardiac muscle cell hypertrophy and change of the interstitial tissue component mainly. In the present invention, the nitrate medicine is used in treatment for myocardial hypertrophy caused by various reasons and excellent therapy effect is obtained. Currently the nitrate medicine is extensively applied in treatment for the coronary heart disease, the heart colicky pain and heart failure. Preload of the heart and myocardial consumption of oxygen are reduced by extension of the venous system. The drugs used in clinical field currently comprise Nitroglycerin, Amyl Nitrite, dicho nitric acid sorbite, sorbide dinitrate, 5-isosorbide dinitrate, Nitroglycerin, pentanitrol ters and itramine tosylate.

The invention discloses a construction method of a diabetic cardiomyopathy animal model. An SD (Sprague Dawley) rat under high-sugar and high-fat feeding is subjected to multiple abdominal injection with STZ (streptozocin); after the diabetics diagnosis standard is reached, subcutaneous injection with isoprenaline is performed; after 2 weeks of continued feeding, left ventricular cannulation and three-lead electrocardiogram test of ventricular hemodynamic parameters and electrocardiogram parameters shows that the rat experiences cardiac dysfunction; heart weight index and left ventricular index show that the rat experiences evident ventricular hypertrophy; biochemical analysis on rat blood shows that the rat has evident myocardial damage; HE (hematoxylin-eosin) pathological staining satisfies pathological changes in diabetic cardiomyopathy; Masson collagen staining satisfies myocardial connective tissue proliferation of diabetic cardiomyopathy. The construction method has the advantages of good operational simplicity, short construction time, low mortality in construction phase, high construction success rate and the like, and the pathological process of myocardial damage due to human type 2 diabetes mellitus can be well simulated.

The invention relates to uses of composition of vitamin C and arginine in antianoxia medicine and health care product. Said composition is prepared into oral taking medicine and health care food acceptable by patent medicine according to common practice. Said invention is characterized by said composition has the effect of antianixia damage, curbing lipid peroxidation , increasing NO output, and decreasing pulmonary artery pressure caused by oxygen shortage and the degree of hypertrophy of right ventricle.

The invention provides application of icariin to the preparation of medicaments for preventing or treating pulmonary artery hypertension and complications thereof. The icariin can reduce pulmonary artery pressure and improve right ventricular hypertrophy, pulmonary heart disease and pulmonary vascular remodeling which are caused by pulmonary artery pressure increase.

The invention relates to a preparation method of saponin of radix adenophorae as well as an application of the saponin of radix adenophorae, which is prepared in accordance with technical scheme of the invention, in treating medicines for treating pulmonary arterial hypertension and related cardiovascular diseases caused by the pulmonary arterial hypertension. Based upon experimental studies, the saponin of radix adenophorae provided by the invention can take an obvious effect on reducing mean pulmonary arterial pressure (MPAP), right ventricle systolic pressure (RVSP) and right ventricular hypertrophy index (RVHI) of the pulmonary arterial hypertension. The saponin of radix adenophorae can be used for preventing and treating one or more diseases of special pulmonary arterial hypertension, heritable pulmonary arterial hypertension, drug and poison related pulmonary arterial hypertension, risk factor or disease related pulmonary arterial hypertension, pulmonary arterial hypertension caused by pulmonary veno-occlusive disease and (or) pulmonarycapillary hemangiomatosis, and neonatal persistent pulmonary arterial hypertension.

The invention discloses a traditional Chinese medicine composition for treating idiopathic pulmonary arterial hypertension. The traditional Chinese medicine composition comprises, by weight, 2-3 parts of white muscardine silkworms, 5-10 parts of herba cistanche, 5-10 parts of radix angelicae pubescentis, 1-3 parts of lotus seed cores, 1-3 parts of dogbane leaves, 5-10 parts of lemon, 0.01-0.05 part of mint, 0.01-0.05 part of pig lung extract and 0.01-0.05 part of Chinese littleleaf box extract. All the raw materials are prepared, smashed, decocted and extracted, then ethyl alcohol is added to serve as a dissolution assistant, and a finished product is obtained. By means of the traditional Chinese medicine composition, pulmonary arterial hypertension can be reduced, pulmonary artery smooth muscle cell proliferation is reduced, blood-vessel-periphery inflammatory cells are obviously reduced, the lesion lung tissue structure and right ventricular hypertrophy can be improved, alveolar-space edema, bleeding and intrapulmonary arteriolar wall and smooth muscle hypertrophy can be relieved, pulmonary vascular resistance can be improved, idiopathic pulmonary arterial hypertension can be effectively treated, and the curative effect is remarkable.

The invention discloses an ervatamia plant extract as well as an extraction and separation method and application thereof. The ervatamia plant extract contains one or more than one bisindole alkaloid selected from bisindole alkaloids E-1 to E-16. The ervatamia plant extract obtained through extraction and separation contains bisindole alkaloid compounds, and can selectively relax pulmonary arteries, inhibit proliferation of pulmonary artery endothelial cells and vascular smooth muscle cells, reduce right ventricular diastolic pressure of pulmonary arterial hypertension mice and inhibit right ventricular hypertrophy. In addition, the series of bisindole alkaloid compounds have chemical structure types different from chemical structure of existing targeted drugs for treating pulmonary arterial hypertension, and the ervatamia plant extract is expected to be developed into novel targeted drugs for treating pulmonary arterial hypertension.

The present invention discloses uses of WNK kinase inhibitors in prevention and / or treatment of pulmonary hypertension, and particularly uses of WNK 463 in the prevention and / or treatment of pulmonary hypertension and complications thereof. Experiments by inventors of the present application find that the WNK kinase inhibitors (especially the WNK 463) show relatively good effects on protection of pulmonic circulation-right-heart pressure and function, right ventricular hypertrophy, etc. of monocrotaline (MCT)-induced pulmonary hypertension in rats, and have potential value of being developedinto drugs for the prevention and treatment of pulmonary hypertension and complications thereof.

The invention discloses a bisindole alkaloid compound as well as a synthesis method and application thereof. The compound has a structure as shown in formula I. In the formula I, R1 is independently selected from C1-C4 alkoxy or hydrogen; if R1 is alkoxy, n is 1 or 2; R2 is independently selected from C1-C4 alkyl groups or hydrogen; R3 is independently selected from a group consisting of C1-C4 alkoxy carbonyl groups or hydrogen; R4 is hydrogen; R5 is independently selected from a C1-C4 alkyl group or a C1-C4 hydroxyalkyl group; and R6 is independently selected from carbonyl, hydroxyl or hydrogen. The bisindole alkaloid compound can selectively relax pulmonary artery, inhibit proliferation of pulmonary artery endothelial cells and vascular smooth muscle cells, reduce right ventricular diastolic pressure of mice with pulmonary arterial hypertension and inhibit right ventricular hypertrophy. The bisindole alkaloid compound can resist drug addiction in a dose-dependent manner, has a chemical structure type different from that of an existing anti-addiction drug, and is expected to be developed into a novel anti-addiction drug.

In some aspects, the disclosure relates to GDF / BMP antagonists and methods of using GDF / BMP antagonists to treat, prevent, or reduce the progression rate and / or severity of pulmonary hypertension (PH), particularly treating, preventing or reducing the progression rate and / or severity of one or more PH-associated complications. The disclosure also provides methods of using a GDF / BMP antagonist to treat, prevent, or reduce the progression rate and / or severity of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, and right ventricular hypertrophy. The disclosure further provides methods of using a GDF / BMP antagonist to reduce right ventricular systolic pressure in a subject in need thereof.

The invention discloses application of aloperine (ALO) to preparation of a medicine for preventing and curing pulmonary arterial hypertension. A rat pulmonary hypertension model is established to explore the protection effect and mechanism of aloperine on rat pulmonary hypertension. The experiment shows that after the pulmonary hypertension model is established, the aloperine can remarkably improve the hemodynamic parameter, the right ventricular hypertrophy index, the lung index, and the echocardiographic parameter, the pathological injury of pulmonary arterioles is improved, the antioxidant ability of a lung tissue is improved, and the malondialdehyde content and the level of nicotinamide adenine dinucleotide phosphate oxidase (NOX)-2 and NOX-4 in the lung tissue are reduced. The aloperine has the effects of inhibiting the development of pulmonary arterial hypertension, oxidative stress and overexpression of NOX-2 and NOX-4.

The invention belongs to the field of medicinal chemistry and provides an application of ciglitazone in preparing drugs for treating pulmonary arterial hypertension. An experiment of the invention proves that ciglitazone is capable of effectively reducing average pulmonary artery pressure and pulmonary vasculature resistance of pulmonary arterial hypertension rats, increasing cardiac output, reducing right ventricular hypertrophy index, improving pulmonary vasculature remodeling and increasing protein expression of Gamma(peroxisome proliferation activated receptor, PPAR Gamma). The experimentproves that ciglitazone has a therapeutic effect on pulmonary arterial hypertension.

Methods are provided for treating pathologies associated with hypoxia with an MIF inhibitor. Methods are also provided for treating a subject having, or at risk for pulmonary hypertension, with an MIF inhibitor. Methods are also provided for reating a subject having, or at risk from, a CNS disorder associated with hypoxia, with an MIF inhibitor. Methods are also provided of treating severe chronic lung disease, hypoxia-induced right ventricular hypertrophy or hypoxia-induced pulmonary vascular remodeling with an MIF inhibitor. Methods of diagnosing a subject with pulmonary hypertension are also provided.

In some aspects, the invention teaches pharmaceutical compositions that include a TGF-β ligand trap, and methods of using a TGF-β ligand trap to treat, prevent, or reduce the progression rate of pulmonary hypertension (PH). The invention also provides methods of using a TGF-β ligand trap to treat, prevent, or reduce the progression rate of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, right ventricular hypertrophy, diseases associated with excessive TGF-β signaling, diseases associated with excessive GDF15 signaling, and diseases associated with excessive PAI-1 signaling. The invention further provides methods of using a TGF-β ligand trap to reduce right ventricular systolic pressure in a subject.

The invention discloses application of tetrahydrocannabivarinic in prevention and / or treatment of pulmonary arterial hypertension, and particularly relates to application of a composition containing tetrahydrocannabivarinic in prevention and / or treatment of pulmonary arterial hypertension and complications thereof. The tetrahydrocannabivarinic, especially a composition containing the tetrahydrocannabivarinic and other cannabinoid Cannabinoids, can significantly reduce right ventricular systolic pressure and right ventricular hypertrophy index of pulmonary arterial hypertension model mice, improve pulmonary edema and hepatic edema, can improve pulmonary arterial hypertension diseases, and especially, the combined administration can enhance the improvement effect on hepatic edema, and has important value for the development of drugs for treating pulmonary arterial hypertension.

The invention relates to a pulmonary hypertension marker and application thereof as a therapeutic target, in particular to the application of a NOC4L gene as the pulmonary hypertension marker and thetherapeutic target. The marker reveals the correlation between the NOC4L gene and pulmonary hypertension for the first time, uses NOC4L overexpression, NOC4L knockout mice and wild type mice to carryout continuous hypoxic environmental treatment, establishes a mouse pulmonary hypertension model, and finds that NOC4L gene overexpression significantly reduces a right ventricular systolic pressure,and significantly increases a right ventricular hypertrophy index and a pulmonary vascular remodeling rate, a right ventricular systolic pressure, a right ventricular hypertrophy index and a pulmonaryvascular remodeling rate of the NOC4L knockout mice. The marker provides a novel target for the research and development of novel drugs for the treatment of the pulmonary hypertension.

In some aspects, the invention teaches pharmaceutical compositions that include a TGF-beta ligand trap, and methods of using a TGF-beta ligand trap to treat, prevent, or reduce the progression rate of pulmonary hypertension (PH). The invention also provides methods of using a TGF-beta ligand trap to treat, prevent, or reduce the progression rate of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, right ventricular hypertrophy, diseases associated with excessive TGF-beta signaling, diseases associated with excessive GDF15 signaling, and diseases associated with excessive PAI-1 signaling. The invention further provides methods of using a TGF-beta ligand trap to reduce right ventricular systolic pressure in a subject.

The present invention is concerned with deuterium-enriched pyrimidine compounds of formula 1, their derivatives and pharmaceutically acceptable salts and methods of use thereoffor the prevention and treatment of neuroendocrine neoplasia including metastasis and fibrosis, fibrotic processes associated with neuroendocrine cell dysregulation for example Crohn's disease, pulmonary arterial hypertension, pulmonary hypertension associated with chronic obstructive pulmonary disease (COPD), right ventricular hypertrophy, pulmonary vascular remodeling, asthma, cystic fibrosis, hypertension, ischemic stroke, angina pectoris, congestive heart failure, arrhythmia, arterial fibrillation, neurodenerative diseases, gastrointestinal disorders , stress disorders, obsessive compulsive disorders, demyelinating diseases, cereberal vascular disorders, bronchoconstriction, vasodilation, smooth muscle contraction, brain disorders, vascular disorders, neuropathological diseases and cardiovascular system regulation.

The invention relates to new pharmacological effects of a compound pinocembrin and an application of pinocembrin to preparation of products for preventing, relieving and / or treating pulmonary hypertension and complications thereof. Pinocembrin has the beneficial effects that pinocembrin has the pharmacological effects of relaxing pulmonary arteries, reducing the pulmonary artery pressure, protecting pulmonary vessels from injuries caused by pulmonary hypertension, restoring lung tissue functions, repairing heart and liver injuries, alleviating right ventricular hypertrophy and enlargement, improving heart failure and liver functions, obviously reducing the mortality of animals with pulmonary hypertension and preventing and treating pulmonary hypertension and complications thereof; pinocembrin is an active monomer separated from a natural product propolis, achieves complete synthesis at present, has good application and development prospects, is an ideal compound for treating pulmonary hypertension and complications thereof and can be applied to preparation of the products for preventing, relieving and / or treating pulmonary hypertension and complications thereof, such as chronic obstructive emphysema, chronic pulmonary heart diseases, right heart failure and liver function injuries.

The invention relates to the field of medical treatment and health care, in particular to the application of melatonin and / or inflammatory body inhibitors in the preparation of drugs for treating pulmonary hypertension. The invention utilizes hypoxia to induce mice to produce pulmonary artery hypertension, mice are then treated with melatonin and inflammatory body inhibitor alone or in combination, the right ventricular hypertrophy index, right ventricular systolic blood pressure and pulmonary pathology are observed, and the effect of melatonin on the pathological development of pulmonary hypertension is confirmed by statistics of vascular remodeling rate, and the effect of melatonin on inflammatory bodies is verified by in vitro cells. The results show that melatonin and inflammatory bodyinhibitor have good therapeutic effect on pulmonary hypertension, and could significantly reduce right ventricular systolic blood pressure, inhibit the activation of inflammatory body, and achieve the purpose of treating pulmonary hypertension. At the same time, the combination of melatonin and inflammatory body inhibitor has more significant effect.

The invention discloses application of golden larch bark acetic acid in preparation of a medicine for treating pulmonary arterial hypertension. The invention belongs to the technical field of biological medicine. A pulmonary arterial hypertension disease mouse model is constructed through hypoxia (10%) induction. After the golden larch bark acetic acid is injected into the intraperitoneal cavity, the conditions of fur, diet, activity, death and the like of the pulmonary arterial hypertension mouse model are observed. Results show that the golden larch bark acetic acid (as shown in the formula I) has the effects of remarkably improving pulmonary vascular remodeling of animals with pulmonary hypertension, relieving right ventricular hypertrophy and right heart failure, improving the life quality of the animals with pulmonary hypertension (improving feeding and water inflow) and increasing the survival rate of the animals with pulmonary hypertension. Therefore, the golden larch bark acetic acid has a wide application prospect in the aspect of preventing and treating the pulmonary arterial hypertension disease.

The present invention is concerned with deuterium-enriched pyrimidine compounds of formula I, their derivatives and pharmaceutically acceptable salts and methods of use thereof,The compounds of formula I are useful for the prevention and treatment of liver fibrosis and cirrhosis, hepatocellular carcinoma, neuroendrcrine neoplasia including metastasis and fibrosis fibrotic processes associated with neuroendocrine cell dysregulation for example Crohn's disease, pulmonary arterial hypertension, pulmonary hypertension associated with chronic obstructive pulmonary disease (COPD), right ventricular hypertrophy, pulmonary vascular remodeling, asthma, cystic fibrosis, hypertension, ischemic stroke, angina pectoris, congestive heart failure, arrhythmia, arterial fibrillation, gastrointestinal disorders, anxiety, depression, stress disorders, post-traumatic stress disorder, obsessive compulsive disorders, demyelinating diseases, acute or chronic cerebrovascular damage, cerebral infarction, subarachanoid hemorrhage, and cerebral edema, neuropathological diseases and cardiovascular system regulation.